EC approves BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
Array BioPharma announced the EC has approved BRAFTOVI® in combination with MEKTOVI® for treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. This approval is applicable to all 28 EU member states, as well as Liechtenstein, Iceland and Norway. September 20, 2018